Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment. A Phase 3 Randomized Clinical Trial

RCT (n= 3754) found no statistically significant difference in disease-free survival between 5 and 2 years of adjuvant zoledronate treatment (HR, 0.97; 95% CI, 0.75-1.25). Adverse events were observed more often with the 5-year (46.2%) vs 2-year (27.2%) zoledronate treatment.

SPS commentary:

SUCCESS-A trial in which 2987 women were randomized to receive zoledronate either for 5 years (4 mg intravenously every 3 months for 2 years, then every 6 months for 3 years) or for 2 years (4 mg intravenously every 3 months). There was also no statistically significant difference in overall survival, distant disease-free survival, and bone recurrence–free survival. There were no discernable trends for subgroups defined by menopausal or hormone-receptor status.

JAMA Oncology

Resource links:

Editorial